半年暴涨近5倍！知名药企拟回A股上市

Core Viewpoint - The company, InnoCare Pharma, plans to return to the A-share Sci-Tech Innovation Board for listing after being listed in Hong Kong for six months, subject to market conditions and necessary approvals [2]. Group 1: Company Overview - InnoCare Pharma was officially listed on the Hong Kong Stock Exchange on April 15, 2025, raising approximately $243 million, making it one of the largest IPOs in the Hong Kong 18A sector in the past four years [4]. - The company's stock price surged by 116.7% on its debut, reaching a peak of HKD 563.5 in September, representing a maximum increase of 495.67% [3][4]. Group 2: Financial Performance - InnoCare Pharma reported revenues of CNY 1.6 million, CNY 1.787 billion, and CNY 1.941 billion for the years 2022 to 2024, primarily from upfront and milestone payments for product licensing [9]. - The net losses for the same years were CNY -387 million, CNY -358 million, and CNY -1.05 billion, with a significant loss of CNY 2.074 billion reported in the first half of 2025, nearly double the loss from 2024 [7][9]. Group 3: Business Focus - The company is focused on innovating next-generation Antibody-Drug Conjugates (ADCs) and has established four globally patented ADC technology platforms, laying a foundation for ongoing innovation [8].